Since the development of epidermal growth factor receptor (EGFR) targeted therapy, antiangiogenic drugs, and the use of intense triplet chemotherapy regimens based on fluoropyrimidines, oxaliplatin, and irinotecan, the treatment of colorectal cancer (CRC) has improved significantly [1]. The gene discussed is EGFR; the disease is colorectal carcinoma.